| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
American College of Chest Physicians (CHEST) 2023 Annual Meeting
|
Venkatesan, Priya
|
|
|
11 |
12 |
p. e100-e101
|
artikel
|
| 2 |
Changing how we see COPD
|
The Lancet Respiratory Medicine,
|
|
|
11 |
12 |
p. 1035
|
artikel
|
| 3 |
Chronic obstructive pulmonary disease: hiding in plain sight, a Statement from the COPD Foundation Medical and Scientific Advisory Committee
|
Bhatt, Surya P
|
|
|
11 |
12 |
p. 1041-1043
|
artikel
|
| 4 |
Core outcome measurement instruments for use in clinical and research settings for adults with post-COVID-19 condition: an international Delphi consensus study
|
Gorst, Sarah L
|
|
|
11 |
12 |
p. 1101-1114
|
artikel
|
| 5 |
Correction to Lancet Respir Med 2023; 11: 1089–100
|
|
|
|
11 |
12 |
p. e98
|
artikel
|
| 6 |
Correction to Lancet Respir Med 2023; published online Nov 1. https://doi.org/10.1016/S2213-2600(23)00298-9
|
|
|
|
11 |
12 |
p. e98
|
artikel
|
| 7 |
COVID-19—an infectious disease in the top five causes of death in Australia
|
Kirby, Tony
|
|
|
11 |
12 |
p. e102-e103
|
artikel
|
| 8 |
Developments in pneumonia and priorities for research
|
Wee, Liang En
|
|
|
11 |
12 |
p. 1046-1047
|
artikel
|
| 9 |
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case–control study
|
Tartof, Sara Y
|
|
|
11 |
12 |
p. 1089-1100
|
artikel
|
| 10 |
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial
|
Hall, Frances C
|
|
|
11 |
12 |
p. 1064-1074
|
artikel
|
| 11 |
Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial
|
Annane, Djillali
|
|
|
11 |
12 |
p. 1051-1063
|
artikel
|
| 12 |
Major gaps in childhood pneumonia research priorities remain
|
Steele, Angharad
|
|
|
11 |
12 |
p. e96-e97
|
artikel
|
| 13 |
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges
|
Shaw, Robert H
|
|
|
11 |
12 |
p. 1038-1039
|
artikel
|
| 14 |
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|
Zhu, Fengcai
|
|
|
11 |
12 |
p. 1075-1088
|
artikel
|
| 15 |
T2-low asthma in school-aged children: unacknowledged and understudied
|
Mishra, Pooja E
|
|
|
11 |
12 |
p. 1044-1045
|
artikel
|
| 16 |
To boost or not to boost: navigating post-pandemic COVID-19 vaccination
|
Goldberg, Yair
|
|
|
11 |
12 |
p. 1039-1041
|
artikel
|
| 17 |
Treatment of severe COVID-19: a role for JAK and complement inhibitors?
|
Goury, Antoine
|
|
|
11 |
12 |
p. 1036-1037
|
artikel
|
| 18 |
US Government finally moves to ban menthol cigarettes
|
Furlow, Bryant
|
|
|
11 |
12 |
p. 1048-1049
|
artikel
|
| 19 |
US nirsevimab shortage forces drug rationing as RSV rates increase
|
Furlow, Bryant
|
|
|
11 |
12 |
p. e99
|
artikel
|
| 20 |
Vernon Lee—using one pandemic to prepare for the next
|
Kirby, Tony
|
|
|
11 |
12 |
p. 1050
|
artikel
|
Tijdschrift beschrijving